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Abstract
Purpose/Objectives—To evaluate the feasibility, usability, and satisfaction of a survivorship 
care plan (SCP) and identify the optimum time for its delivery during the first 12 months after 
diagnosis.
Design—Prospective, descriptive, single-arm study.
Setting—A National Cancer Institute–designated cancer center in the southeastern United States.
Sample—28 nonmetastatic colon cancer survivors within the first year of diagnosis and their 
primary care physicians (PCPs).
Methods—Regular screening identified potential participants who were followed until treatment 
ended. An oncology certified nurse developed the JourneyForward™ SCP, which then was 
delivered to the patient by the oncology nurse practitioner (NP) during a routine follow-up visit 
and mailed to the PCP.
Main Research Variables—Time to complete, time to deliver, usability, and satisfaction with 
the SCP.
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Findings—During one year, 75 patients were screened for eligibility, 34 SCPs were delivered, 
and 28 survivors and 15 PCPs participated in the study. It took an average of 49 minutes to 
complete a surgery SCP and 90 minutes to complete a surgery plus chemotherapy SCP. Most 
survivors identified that before treatment ended or within the first three months was the preferred 
time to receive an SCP.
Conclusions—The SCPs were well received by the survivors and their PCPs, but were too time 
and labor intensive to track and complete.
Implications for Nursing—More work needs to be done to streamline processes that identify 
eligible patients and to develop and implement SCPs. Measuring outcomes will be needed to 
demonstrate whether SCPs are useful or not.
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Cancer survivorship care represents a distinct phase of the cancer care trajectory and 
includes four components of care (Hewitt, Bamundo, Day, & Harvey, 2007). The 2007 
Institute of Medicine (IOM) report Implementing Cancer Survivorship Care Planning 
(Hewitt & Ganz, 2007) recommended providing cancer survivors and their primary care 
provider (PCP) with a treatment summary and a care plan as a component of survivorship 
care. More recently, the American Society of Clinical Oncology (ASCO) identified 
survivorship care plans (SCPs) as part of high-quality cancer survivorship care, enhancing 
communication and coordination of care between providers and the patient (McCabe & 
Jacobs, 2008). Since the IOM recommendations were issued, clinicians have struggled to 
develop and implement SCPs because of time constraints, lack of development 
reimbursement, and challenges in health information systems (Jacobs et al., 2009; Schrag, 
2006). Because knowledge about SCP development, implementation, and outcomes is 
nascent, evaluation of system- and patient-level processes and outcomes are needed (Earle, 
2007).
Individuals diagnosed with colon cancer comprise the third largest group of male and female 
cancer survivors in the United States, with over one million survivors (National Cancer 
Institute, 2014); therefore, treatment and ongoing surveillance are critical for this high-risk 
population (Figueredo et al., 2003). To improve outcomes, survivors need to learn about 
surveillance, health maintenance, and health-promotion recommendations to decrease the 
risk of recurrence and to facilitate early detection (Desch et al., 2005; Hewitt et al., 2007; 
Hewitt, Greenfield, & Stovall, 2005).
Stage I, II, or III colon cancer is treated with surgery. Adjuvant chemotherapy generally is 
recommended for stage III and some high-risk stage II colon cancers (i.e., those with 
obstruction or tumor adherence to adjacent structures) to prevent or delay recurrence and 
improve survival (Benson et al., 2011). Following recommended surveillance after the 
completion of treatment has been shown to decrease mortality; however, adherence to this 
evidence-based schedule is low (Desch et al., 2005; Faul et al., 2012; Faul, Shibata, 
Townsend, & Jacobsen, 2010; Snyder, Earle, Herbert, Neville, Blackford, & Frick, 2008a, 
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2008b). Cancer and its treatment can cause permanent body changes (e.g., surgical scarring) 
and symptoms that may last for years or be permanent (e.g., peripheral neuropathies, 
diarrhea or frequent bowel movements), along with other physical and psychosocial 
sequelae that also may need to be addressed (Edwards et al., 2002; Hewitt & Rowland, 
2002; Schlairet, Heddon, & Griffis, 2010). To monitor for the recurrence or occurrence of 
new colon cancers in patients with stage II or III disease, ASCO guidelines recommend 
routine surveillance with a history and physical examination, a carcinoembryonic antigen 
blood test, an annual chest and abdominal computed tomography scan, and a colonoscopy 
within the first three years after diagnosis and then every five years for those at normal risk 
or as directed by the results (Desch et al., 2005).
SCPs provide a communication tool for providers and patients. A number of surveys have 
been conducted asking PCPs, oncologists, and patients about the use of SCP. Although they 
all endorse the concept of an SCP (Baravelli et al., 2009; Watson, Sugden, & Rose, 2010), 
less consensus exists as to who should prepare and deliver it, and when that delivery should 
occur within the cancer continuum. The optimal timing of SCP delivery from survivors’ or 
providers’ perspectives has not yet been determined.
Given the discordant views of who should administer certain aspects of care to survivors 
(Cheung, Neville, Cameron, Cook, & Earle, 2009; Cheung, Neville, & Earle, 2010), 
delivering a copy of the SCP to both the patient and the PCP may foster communication 
among the oncologist, survivors, and the PCP as well as promoting shared care, adherence to 
screening, and health promotion. As the projected growth in cancer survivors and shortage 
of oncologists will most likely shift care back to the PCPs, this becomes increasingly 
important. In recent analyses of an online SCP, 53% percent of participants reported follow-
up care from only their oncologist, 13% from only their PCP, and 32% from both; few 
participants (12%) received survivorship information (Hill-Kayser, Vachani, Hampshire, 
Jacobs, & Metz, 2009). Evaluating the process of delivering SCP to the survivor and PCP is 
needed.
JourneyForward™ provides free web-based SCP templates created in collaboration with the 
National Coalition for Cancer Survivorship; University of California, Los Angeles Cancer 
Survivorship Center; Oncology Nursing Society; WellPoint, Inc; and Genentech 
(www.journeyforward.org). JourneyForward SCPs have templates for treatment summaries 
and surveillance, with a version specifically adapted for colon cancer survivors. Therefore, 
this pilot study developed, implemented, and evaluated the feasibility, acceptability and 
satisfaction of the JourneyForward SCP for stage I–III colon cancer survivors from both the 
survivor and provider perspectives.
Methods
This was a descriptive study of colon cancer survivors treated at a National Cancer Institute 
(NCI)–designated comprehensive cancer center in the southeastern United States and their 
PCPs conducted over one calendar year.
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Patients with stage I, II, or III colon cancer who had completed treatment and were within 
the first year of diagnosis were eligible. Participants also had to be older than 21 years and 
able to read and speak English.
Institutional review board approval was received, and potentially eligible patients were 
identified at the weekly gastrointestinal (GI) tumor board meeting where all patients newly 
diagnosed with colon cancer are presented. Their electronic medical records were screened 
for eligibility and then followed on a weekly basis for appointments. To recruit other 
potentially eligible colon cancer survivors, the study program manager reviewed weekly 
schedules of the 11 GI oncology providers. Once a potentially eligible patient was identified, 
an SCP was developed using the JourneyForward template by an oncology certified nurse 
(OCN®) trained in its use. Any discrepancies or questions were reviewed by the medical 
oncologist on the team. The OCN kept a log of how long it took to complete each SCP and 
any issues that arose in preparing it. The nurse practitioner (NP) for the surgical or medical 
oncology team was notified the week the patient was scheduled for a follow-up appointment 
and was given the patient’s SCP. The SCP draft was reviewed and finalized by the NP and 
then reviewed with the patient.
After completing the SCP review with the patient, the NP briefly described the study and 
requested permission for a follow-up contact by study personnel; study personnel then 
obtained informed consent when first contacting the patient. SCPs were delivered 6–12 
weeks after completion of the patient’s treatment or at any scheduled return visit from 3–12 
months after diagnosis. The SCP visit was billed using length of time at a level four or five 
evaluation and management code with appropriate documentation for Centers for Medicare 
and Medicaid Services reimbursement (Schrag, 2006). The NP kept a log of the visits, 
including length of time to deliver the SCP verbally and in print, as well as any issues 
regarding the tool or visit. The study personnel then contacted the patient at home and 
completed the study measures by phone two weeks after the visit; patients were sent a $20 
gift card and a copy of NCI’s Facing Forward: Life After Cancer Treatment.
A paper copy of the SCP was sent by mail to the PCP on record along with a cover letter and 
a review article (Ganz, 2009) on the care of adult cancer survivors (Mayer, Gerstel, Leak, & 
Smith, 2012). Follow-up by the program manager with the PCPs was conducted within two 
weeks of SCP delivery with a mailed followup survey. A reminder was sent two weeks later 
if the survey had not been returned. Return of the survey reflected consent from the PCP.
Measures
Demographic and medical information were collected from the participant and his or her 
medical record. Logs were completed to track the process of developing and implementing 
SCPs.
A modified System Usability Scale (SUS) (Brooke, 1996) was used to evaluate the SCP 
tool from the PCPs’ and survivors’ perspectives (Sauro, 2011). The measure consists of six 
items with a five-point Likert-type scale ranging from 1 (strongly disagree) to 5 (strongly 
agree). Comments were solicited about each section of the SCP and usability of the SCP 
overall.
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An adapted version of the Agency for Healthcare Research and Quality’s Consumer 
Assessment of Healthcare Providers and Systems Adult Specialty Care Clinician 
Questionnaire (Hargraves, Hays, & Cleary, 2003) was used, including eight items regarding 
care received from NPs, including provider communication, health promotion and 
education, help with problems or concerns, and demographics (Cronbach alpha > 0.75). A 
six-point Likert-type scale ranging from 1 (not at all) to 6 (all the time) was used. 
Participants also were asked to add any comments about the SCP.
Descriptive statistics were computed for all variables for each participant. Continuous 
variables were summarized using means, standard deviations, medians, minima, and 
maxima. Categorical variables were summarized with frequencies and percentages. 
Reliability coefficients were computed for all scales.
Results
Seventy-five patients were screened, 49 patients were eligible and had an SCP developed, 
and 34 SCPs were delivered; a total of 28 survivors and 15 PCPs participated in this study 
(see Figure 1). Fifteen patients were considered lost to follow-up as they did not receive 
their SCP; 28 of those who received their SCP agreed to participate in the study. Of the 28 
survivors, 11 had surgery only and 17 had surgery and chemotherapy (see Table 1). Surgery-
only survivors were predominantly female, older, Caucasian, married, and had a high school 
education. Survivors who received surgery and chemotherapy were more likely to be male, 
younger, and college educated. PCPs were female, physicians, younger than 50 years, and in 
practice an average of 23 years (see Table 2).
It took the OCN an average of 49 minutes (SD = 27, range = 30–90) to complete a surgery 
SCP and 90 minutes (SD = 48, range = 45–210) to complete a surgery and chemotherapy 
SCP. Although the authors’ institution uses electronic health records, chemotherapy was 
documented in separate electronic and paper records, which meant accessing multiple 
physical and electronic sites to complete the SCP. In addition, clinic notes did not 
consistently or clearly document side effects and changes in chemotherapy drugs or dosing, 
which needed to be included in the SCP, accounting for the increased preparation time 
compared to the surgeryonly participants.
A total of 34 SCPs were delivered to patients; 6 were not delivered because of missed 
appointments or extremely busy clinics on the day they were to be delivered. Delivery took 
an average of 16 minutes (SD = 2, range = 15–20) for the surgery SCP, and 26 minutes (SD 
= 2.2, range = 25–30) for the surgery and chemotherapy SCP during a regularly scheduled 
surveillance visit. At the end of the study, the NPs did not feel an SCP added time to the 
regular visit, but provided more structure when reviewing the information contained within 
the SCP.
Almost all survivor participants found the SCP easy to use and understand (see Table 3). 
Although some thought they would need help using it, the SCP received high satisfaction (
= 5, SD = 0.56) and usability (  = 4, SD = 0.38) ratings from survivors. PCPs rated the 
usability of the SCP highly (  = 4, SD = 0.5) but commented that it was too long for their 
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use (see Table 4). Written comments from patients and PCPs were reviewed by the study 
team; all were positive and related to the reassurance the written plan provided.
Eighteen participants thought the SCP should be delivered either before the end or within 
the first three months of completing treatment. In addition, survivors were highly satisfied 
(5.4/6) with their SCP visit. Twenty-seven survivor participants felt enough time was spent 
on their visit, and that they had things explained to them, and 26 felt that were encouraged to 
ask questions.
Discussion
Many patients with cancer find the transition from acute treatment to extended survival 
difficult (Hewitt et al., 2005). Survivors may not know the significance of surveillance, in 
particular, what tests need to be done, who to see, or how often to go for follow-up visits 
once treatment is over. Many do not receive the recommended follow-up care for colon 
cancer (Cooper & Doug Kou, 2008; Davies et al., 2012; Earle & Neville, 2004).
This study was conducted for one type of cancer in a single institution. Attrition at each step 
of the process demonstrates the difficulty in conducting studies mirroring clinical practice 
(for example, one of the two NPs had maternity leave during the study and patients were 
missed during this time). Because the study was limited to one year, researchers were not 
able to follow the patients and providers over time to measure outcomes such as adherence 
to the surveillance guidelines. Although these issues limit generalizability, the study did 
provide an in-depth look at the logistics behind the development and implementation of an 
SCP. The greatest barriers in the development and implementation of SCPs were identifying 
the patients and delivering the SCP during busy clinical practices. If electronic health 
records could be developed and programmed to populate the SCP and alert the provider 
when a patient might be due for an SCP, much of the development time could be reduced, 
making this a more feasible intervention.
A number of studies have been conducted on patients’ and PCPs’ preferences and 
experiences (Kantsiper et al., 2009; Lawler, Spathonis, Masters, Adams, & Eakin, 2011; 
Lewis et al., 2009; Nissen et al., 2007; O’Malley & Cunningham, 2009; Rowland, 2008; 
Skolarus et al., 2011). Faul et al. (2012) conducted in-depth interviews with seven colon 
cancer survivors who had received an SCP and their respective oncology providers from one 
setting (Faul et al., 2012). The survivors found the printed SCP versions very helpful and 
used them as a guide for care, many sharing with others and bringing them to appointments. 
Survivors also saw value in the SCP as a tool to help reduce duplication of testing, 
addressing their fear of recurrence and providing peace of mind. Oncology providers 
generally were supportive but did raise concerns about the logistics of their development, 
sustainability, and impact on outcomes (Potosky et al., 2011). PCPs may not feel they have 
the information they need to provide survivorship care to colorectal cancer survivors (Salz, 
Oeffinger, Lewis, et al., 2012; Salz, Oeffinger, McCabe, Layne, & Bach, 2012); the SCP 
could be one means to deliver that information.
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Although still nascent, a growing number of studies are evaluating the outcomes of SCP 
delivery (Grunfeld et al., 2011; Hershman et al., 2013; Nissen, Tsai, Blaes, Swenson, & 
Koering, 2013). Grunfeld et al. (2011) conducted a randomized, controlled trial of 408 
Canadian women with breast cancer at a mean of 35 months after diagnosis. The women 
either acted as controls and received a discharge visit prior to returning to their PCP, or they 
were in the intervention group and received an SCP (Grunfeld et al., 2011). The only 
significant differences between the two groups were found in knowledge of follow-up care. 
Those who received the SCP significantly identified that their PCP was responsible. The 
researchers did not describe the process or time needed to complete the SC, but they were 
delivered by a nurse during a 30-minute session during the discharge visit. Hershman et al. 
(2013) randomized women with breast cancer to receive the NCI’s Facing Forward: Life 
After Cancer Treatment booklet with or without meeting an NP and nutritionist who 
delivered an SCP six weeks after completing treatment. Women in the intervention group 
had less worry at three, but not six, months afterward. Again, the researchers did not 
describe the process or content of SCP development. Nissen et al. (2013) sent treatment 
summaries by mail to colorectal and breast cancer survivors who were eight years post-
diagnosis, and then surveyed them 17 months later. Although knowledge about diagnosis 
did increase, it was still very low. Again, no details were given about SCP development.
Other studies have looked at variations within practice, such as the percent of oncology 
providers or programs reporting developing and delivering SCPs and of PCPs who have 
received them (Howell et al., 2012; Merport, Lemon, Nyambose, & Prout, 2012; Salz, 
Oeffinger, McCabe, et al., 2012). Adoption of the 2005 IOM recommendation has been slow 
(Birken, Mayer, & Weiner, 2013; Chubak et al., 2012; Stricker et al., 2011; Stricker, Jacobs, 
& Palmer, 2012), which may, in part, be because of barriers to development and lack of 
significant benefits in patient outcomes (Grunfeld & Earle, 2010; Hershman et al., 2013; 
Stricker et al., 2011). However, the American College of Surgeon’s (2012) Commission on 
Cancer has adopted a standard that requires that by 2015,
The cancer care committee develops and implements a process to disseminate a 
comprehensive care summary and follow-up plan to patients with cancer 
completing cancer treatment. A survivorship care plan is prepared by the principal 
provider(s) who coordinated the oncology treatment, is given to the patient on 
completion of treatment, contains a record of care received, important disease 
characteristics, and a written follow-up plan. (p. 78)
More work needs to be done to improve the development and implementation process of 
SCPs to increase adoption (Salz, Oeffinger, McCabe, et al., 2012; Wolin, Colditz, & Proctor, 
2011). Electronic health records may lessen the development time of SCPs but other process 
issues still need to be addressed, such as systematically identifying eligible patients, the 
timing of delivery, and the provider responsible for delivering the SCP to the patient and 
sharing it with the PCP. Institutional cancer committees may champion or provide support to 
attend to this process. As SCPs become disseminated more widely, survivor outcomes may 
be measured. For example, do SCPs increase adherence to surveillance recommendations? 
Do they reduce redundant testing or promote more evidence-based surveillance? Is it the 
SCP that makes the difference or the survivorship visit when it is delivered? Lessons learned 
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about implementation of the SCP from this study also can be used for implementation and 
evaluation in other settings or with other types of cancer. Given the new Commission on 
Cancer’s standard on SCPs, these issues will need to be addressed.
Knowledge Translation
Survivorship care plans (SCPs) will be required as evidence of quality cancer care in new 
standards by the American College of Surgeon’s Commission on Cancer.
Nurses will serve a key role in addressing those standards in their practices.
Organizations will need to address the time and resources needed to develop SCPs before 
questions about effectiveness can be addressed.
Limitations
This study was done in a single academic center focusing on one tumor population, which 
limits generalizability to other types of practice settings and populations. It does, however, 
identify a process for implementation and evaluation that may be useful in other settings.
Implications for Nursing
Before asking questions about effectiveness, SCPs must be developed and implemented. 
Long-term studies on the use of SCPs are needed to measure patient and provider outcomes 
(Haq et al., 2013; Hill-Kayser et al., 2013). As more institutions move to electronic health 
records, there may be ways to semi-automate the development of SCPs to facilitate 
completion in a more streamlined manner. However, systems will still need to be in place to 
identify, track, and evaluate their implementation in cancer programs.
Nurses will be instrumental in addressing the development and implementation of SCPs in 
cancer practices. Participation in cancer committees also will be necessary to raise system 
issues to make this practice possible for the majority of patients ending their cancer 
treatment. Systems that identify eligible patients and how to develop, deliver, and document 
this activity will be important in meeting this Commission on Cancer standard.
Conclusions
This pilot study developed, implemented, and evaluated the feasibility, usability, and 
satisfaction of the JourneyForward SCP from both the survivor (n = 34) and provider (n = 
15) perspectives. A number of issues prevented all of the developed SCPs from being 
delivered. For example, it took an average of 49 minutes to complete a surgery SCP and 90 
minutes to complete a surgery and chemotherapy SCP. Survivors also preferred receiving 
the SCP just before treatment ended or within the first three months. The SCPs were well 
received by the survivors and their PCPs. This process needs to be streamlined to encourage 
more widespread adoption. Only then will researchers determine whether SCPs help 
facilitate care coordination and communication to improve the quality of cancer care (Parry, 
Kent, Forsythe, Alfano, & Rowland, 2013).
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Table 1
Sample Characteristics (N = 28)











Age (years) 56 13.4 35–87 62 15.8 39–87 52 10.5 35–70
Time since diagnosis (months) 9 3.2 3–13 9 3.2 3–13 10 2.3 6–13
Characteristic n n n
Gender
 Male 15 5 10
 Female 13 6 7
Race
 Caucasian 23 10 13
 African American 5 1 4
Marital status
 Married 18 8 10
 Other 10 3 7
Education
 High school 11 6 5
 Some college 1 1 –
 College or more 16 4 12
Insurance type
 Private 15 5 10
 Medicare 7 4 3
 Medicaid 4 1 3
 Missing data 2 1 1
Stage
 I 7 6 1
 II 9 5 4
 III 12 – 12
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Table 2
Primary Care Providers’ Demographics (N = 15)
Characteristic X
‒ Range





 Younger than 50 9
 50 and older 6
Role
 Medical doctor 13
 Other 2
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Table 3
Patient Evaluation of the Survivorship Care Plan (SCP) (N = 28)
Total Surgery Only (n = 11)
Surgery and Chemotherapy
(n = 17)
Patient-Centered Communication Agree or Strongly Agree Agree or Strongly Agree Agree or Strongly Agree
Explained things so I can understand 27 11 16
Listened carefully to me 24 11 13
Easy to understand 27 11 16
Showed respect 26 11 15
Checked my understanding 25 11 14
Spent enough time 27 11 16
Encouraged questions 26 11 15
Talked about specific things 26 11 15
SCP Usability Agree or Strongly Agree Agree or Strongly Agree Agree or Strongly Agree
Easy to understand 26 10 16
Simple to use 26 10 16
Good length 24 9 11
Useful 27 11 16
Covered correct topics 27 11 16
Needed help using it 7 4 2
Best time to receive the SCP
 Before treatment ends 8 2 7
 3 months post-treatment 10 7 –
 6 months post-treatment 8 2 7
 9 months post-treatment 2 – 3
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Table 4
Provider Evaluation of the Survivorship Care Plan (N = 15)
Survivorship Care Plan Usability Agree or Strongly Agree
Easy to understand 14
Good length 9
Useful 14
Covered correct topics 14
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